Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

NCT07422779 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma
Skin Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Institute of Oncology Ljubljana